Conference Linked to as Many as 300,000 COVID-19 Cases: Study

Around 100 people were infected at a scientific meeting hosted by Biogen in Boston in February. Then they went back home, taking the virus with them.

Written byLisa Winter
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM,
METAMORWORKS

The United States had its first coronavirus superspreader event during a two-day conference in Boston organized by the biotech company Biogen in February. Genetic testing has revealed that what began with 99 people who became infected with SARS-CoV-2 at the event, another 205,000–300,000 cases subsequently resulted as the attendees returned home to 29 states and several other countries, carrying the virus with them, according to a study published in Science on December 10.

A national database of SARS-CoV-2 genomes and contact tracing has allowed the authors to track which strains were being transmitted. As The Boston Globe reports, the proportion of the pandemic attributed to the conference is roughly 1.6 percent of all US COVID-19 cases.

By performing genetic analyses from 28 of the infected conference-goers, researchers were able to identify the viral strain that circulated among them and that then spread around the country. They ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Lisa joined The Scientist in 2017. As social media editor, some of her duties include creating content, managing interactions, and developing strategies for the brand’s social media presence. She also contributes to the News & Opinion section of the website. Lisa holds a degree in Biological Sciences with a concentration in genetics, cell, and developmental biology from Arizona State University and has worked in science communication since 2012.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies